Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company engaged in manufacturing of pharmaceuticals and intermediate drugs. The Company specializes in developing and manufacturing bulk drugs and pharmaceutical formulations. It manufactures capsules, tablets and ampoules. It operates research and development, manufacturing, marketing and distribution facilities. It develops and manufactures active pharmaceutical ingredients (APIs) and formulations. It offers products under various brands, including Lycored, which contains lycopene with phytonutrients; Maintane, which contains allylestrenol; Metadec, which contains nandralone decanoate; Metabol, which contains nandralone phenyl propionate; Doxypal DR, which contains doxycycline delayed release; Parvon, and Indocap SR, which contains indomethacin sustained release. It has operations in Russia, Brazil, the United States, Ukraine, Sri Lanka, Cameroon, Thailand, Argentina, Germany, Switzerland, Korea, Egypt and Vietnam.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.